Skip to main content
. 2023 Aug 31;9:128. doi: 10.1038/s41531-023-00573-2

Table 1.

Cohort summary statistics.

Cohort PD patients Post-QC (n) Follow up, years No.(%) LiD No.(%) left-censored No.(%) male Time to midpoint event (mean ± sd) AAO, years (mean ± sd) AAB, years (mean ± sd) Disease duration at baseline from onset, years (mean ± sd) MDS-UPDRS part III at baseline (mean ± sd) Levodopa dose at baseline (mean ± sd)
Tracking Parkinson’s 1478 7.5 177 (12) 16 (1) 945 (64.23) 7.47 (2.18) 64.43 (9.16) 67.29 (9) 2.86 (1.58) 22.36 (11.69) 217 (197)
OPDC 705 9.0 92 (13) 8 (0.8) 451 (64) 7.87 (2.87) 64.35 (9.47) 67.21 (9.26) 2.85 (1.70) 26.27 (10.82) 280 (205)
PPMI 283 9.0 82 (21) 0 (0) 259 (66) 8.28 (2.27) 60.16 (9.93) 62.08 (9.78) 1.92 (1.30) 21.38 (9.10) 0 (0)
PD STAT 77 2.0 10 (13) 4 (4.9) 48 (62) 8.77 (2.83) 57.23 (8.7) 64.84 (9.24) 7.61 (1.73) 28.86 (11.61) NA
PDBP 241 5.0 33 (14) 16 (6) 149 (62) 5.93 (2.66) NA 64.58 (9.3) 2.85 (2.51) 20.9 (11.11) 414 (207)

No. (%) of LiD. This is the percentage with respect to (n).

No. (%) of left-censored. This is the percentage of left-censored patients with respect to (n).

No.(%) male. This is the percentage of males with respect to (n).

MDS-UPDRS part III (mean ± sd). MDS-UPDRS part III total at baseline.